{'fraction_non_alphanumeric': 0.038288288288288286, 'fraction_numerical': 0.038288288288288286, 'mean_word_length': 5.786259541984733, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Vancomycin‐resistant enterococcus in pediatric oncology patients: An analysis of potential consequences of colonization and infection

A retrospective analysis of 57 pediatric oncology patients with a baseline positive vancomycin‐resistant enterococcus (VRE) culture who subsequently received chemotherapy and/or radiation therapy was performed. The incidence of subsequent VRE infection was calculated using a competing risk analysis accounting for death from non‐VRE causes as a competing risk. Ten patients had subsequent VRE infection. The cumulative incidence of subsequent infection was 14% (7–27%, 95% confidence interval) at 1 year and 16% (9–29%, 95% confidence interval) at 2 years. None of the hypothesized risk factors appeared to differ between patients who developed a subsequent infection and those who did not. Pediatr Blood Cancer 2009;52:300–302. © 2008 Wiley‐Liss, Inc.